<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7549853\results\search\testTrace\results.xml">
  <result pre="order to produce a concise overview of the pathogenesis and" exact="treatment" post="of SARS-CoV-2 (COVID-19 [coronavirus disease 2019]) for clinicians. This"/>
  <result pre="the pathogenesis of SARS-CoV-2. In addition, a thorough review of" exact="treatment" post="options including oxygenation/ventilation strategies, dexamethasone, remdesivir, chloroquine/hydroxychloroquine, immune-based therapies,"/>
  <result pre="these topics. covid19 sars-cov-2 covid induced ards covid-19 management sars-cov-2" exact="infection" post="sars-cov-2 pathogenesis sars-cov-2 induced ards sars-cov-2 treatment remdesivir dexamethasone"/>
  <result pre="covid-19 management sars-cov-2 infection sars-cov-2 pathogenesis sars-cov-2 induced ards sars-cov-2" exact="treatment" post="remdesivir dexamethasone The content published in Cureus is the"/>
  <result pre="a concise yet comprehensive overview of the basic pathogenesis and" exact="treatment" post="of SARS-CoV-2 for clinicians. Review Study acquisition Articles were"/>
  <result pre="ferritin)Â [15-17]. This dysregulated host immune response to SARS-CoV-2 lung" exact="infection" post="leading to exuberant cytokine release (cytokine storm) and resultant"/>
  <result pre="NA 39% 80% Coagulopathy NA &amp;lt;1% NA &amp;lt;1% 63% Hospital-acquired" exact="infection" post="NA NA NA NA 17% Interestingly, the pediatric population"/>
  <result pre="varied greatly depending on the duration of ARDS prior to" exact="treatment" post="initiation with corticosteroids. For example, patients receiving corticosteroids greater"/>
  <result pre="supporting its use in early ARDS, corticosteroid use for the" exact="treatment" post="of viral infections has been a controversial due to"/>
  <result pre="explore more of the potential benefits of corticosteroids in the" exact="treatment" post="of SARS-CoV-2Â [37]. The study compared patients treated with"/>
  <result pre="statistically significant reductions in 28-day mortality among patients within the" exact="treatment" post="arm. This effect seems to be influenced by the"/>
  <result pre="cardiac arrhythmias, and receipt/duration of ventilation for patients among the" exact="treatment" post="arm, is warrantedÂ [37]. In the event that dexamethasone"/>
  <result pre="indicated a significant reduction in time to recovery among the" exact="treatment" post="arm (11 vs 15 days). Subgroup analysis revealed that"/>
  <result pre="days of remdesivirÂ [41]. Despite the similar rates with both" exact="treatment" post="durations, it is still unclear if critically-ill patients are"/>
  <result pre="BID for 10 days) or hydroxychloroquine plus azithromycin for the" exact="treatment" post="of SARS-CoV-2Â [24]. Chloroquine and its analog hydroxychloroquine have"/>
  <result pre="studies. Studies on chloroquine have shown minimal efficacy in the" exact="treatment" post="of SARS-CoV-2 and increased mortality when taking the high-dose"/>
  <result pre="reduced risk of death/intubationÂ [44]. While others have shown no" exact="treatment" post="benefits among patients receiving hydroxychloroquine Â± azithromycin compared with"/>
  <result pre="not approve the use of hydroxychloroquine and chloroquine for the" exact="treatment" post="of SARS-CoV-2Â [24]. Immune-Based Therapies On August 23, 2020,"/>
  <result pre="authorization (EUA) for the use of convalescent plasma in the" exact="treatment" post="of SARS-CoV-2, stating that the â€œpotential benefits outweigh the"/>
  <result pre="for or against the use of convalescent plasma in the" exact="treatment" post="of SARS-CoV-2Â [24]. Convalescent plasma utilizes the principle of"/>
  <result pre="sample was insufficient to determine subtle clinical differences among the" exact="treatment" post="armsÂ [48]. In addition, a safety analysis conducted on"/>
  <result pre="is unlikely that the plasma of donors without confirmed SARS-CoV-2" exact="infection" post="contain high titers of SARS-CoV-2 neutralizing antibodies. Additionally, it"/>
  <result pre="HMG-CoA reductase inhibitors for certain chronic conditions prior to a" exact="diagnosis" post="of SARS-CoV-2 should not discontinue their therapyÂ [24]. Patients"/>
  <result pre="a concise summary of relevant literature on the pathogenesis and" exact="treatment" post="of SARS-CoV-2. Information on this topic is changing rapidly,"/>
  <result pre="Thus, the medical community is racing to find the perfect" exact="treatment" post="combination against SARS-CoV-2 by blending remdesivir with other drugs"/>
  <result pre="studies are currently underway to evaluate its use for both" exact="treatment" post="and prophylaxis of certain high-risk patients. Despite the recent"/>
  <result pre="persistent acute respiratory distress syndromeN Engl J MedSteinbergKPHudsonLDGoodmanRBet al.16711684354200616625008 34Dexamethasone" exact="treatment" post="for the acute respiratory distress syndrome: a multicentre, randomised"/>
  <result pre="with severe Covid-19N Engl J MedGreinJOhmargariNShinDet al.23272336382202032275812 40Remdesivir for the" exact="treatment" post="of COVID-19-preliminary reportN Engl J MedBeigelJHTomashekKMDoddLEet al.9929943832020 41Remdesivir for"/>
  <result pre="43Treating COVID-19 with chloroquineJ Mol Cell BiolHuangMTangTPangPet al.32232512202032236562 44Association of" exact="treatment" post="with hydroxychloroquine or azithromycin with in-hospital mortality in patients"/>
  <result pre="in 20,000 hospitalized patients [PREPRINT]Mayo Clin ProcJoynerMJBrunoKAKlassenSAet al.18881897852020 50Association of" exact="treatment" post="dose anticoagulation with in-hospital survival among hospitalized patients with"/>
 </snippets>
</snippetsTree>
